The Ubiquitin Proteasome market studied is anticipated to grow with a CAGR of nearly 3.9%, during the forecast period.
Certain factors that are driving the market growth include rising prevalence of cancer and neurodegenerative diseases and an increase in research and development activities. According to the WHO, Cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries.
As data is being generated aggressively in the healthcare sector, a few developing countries have surpassed the lack of data, and it is likely to become so in the remaining countries as well. This augmentation of data is expected to provide the basis for any national policy on cancer. In turn, this factor may possibly lead to an increase in the percentage of people opting for cancer treatment.
Additionally, with increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. According to a study by the Parkinson’s Disease Foundation, the number of new cases of the disease has increased over the last 30 years. Globally, over 10 million people are living with Parkinson's disease, according to the statistics of 2016. The Alzheimer's Association stated that around 5.4 million people in the United States were living with Alzheimer’s disease, in 2016.
Key Market Trends
Cancer Holds Significant Share in the Treatment Market
- Globally, cancer is one of the leading causes of death. The disease witnessed significant growth in the last few decades, and it is expected to grow rapidly over the forecast period. The World Health Organization (WHO) estimates the rate of cancer number to increase to 70% over the next two decades.
- Additionally, the increased burden of several lifestyle disorders is also expected to drive the market. As per the American Cancer Society, in 2018, the United States witnessed around 164,690 new cases of prostate cancer, causing over 26,430 deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. In order to tackle such challenges, extensive research in the field of therapeutics has been undertaken. Overall, with such a high prevalence rate of cancer across the world, the demand for Ubiquitin Proteasome is sure to rise, in turn, leading to the growth of this segment in the years to come.
North America Dominates the Global Ubiquitin Proteasome Market
The United States has witnessed a considerable rise in the number of cancer patients. According to the American Cancer Society, in 202, there will be approximately 89,500 cancer cases diagnosed and about 9,250 cancer deaths in adolescents and young adults (AYAs) ages 15 to 39 years in the US. Prostate and breast cancers are the most prevalent forms of cancer in the region.
Similarly, according to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson's disease (PD) will continue to grow, and this is expected to double by 2040.
The global Ubiquitin Proteasome market is competitive and consists of a few major players. Companies like BioVision Inc., Promega Corporation, Merck KGaA, Takeda Pharmaceutical, Tocris Bioscience, among others, hold a substantial market share in the market.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer and Neurodegenerative Diseases
4.2.2 Increase in Research and Development Activities
4.3 Market Restraints
4.3.1 High Cost of the Drug and Stringent Regulations
4.3.2 Side Effects associated with Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Scientific Research
220.127.116.11 Neurodegenerative Disease
5.2.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.2.5 South America
22.214.171.124 Rest of South America
6.1.1 BioVision Inc.
6.1.2 Promega Corporation
6.1.3 Merck KGaA
6.1.4 Takeda Pharmaceutical
6.1.5 Tocris Bioscience
A selection of companies mentioned in this report includes:
- BioVision Inc.
- Promega Corporation
- Merck KGaA
- Takeda Pharmaceutical
- Tocris Bioscience